Real-world persistence of multiple sclerosis disease-modifying therapies.
Tallantyre EC, Dobson R, Froud JLJ, St John FA, Anderson VM, Arun T, Buckley L, Evangelou N, Ford HL, Galea I, George S, Gray OM, Hibbert AM, Hu M, Hughes SE, Ingram G, Kalra S, Lim CE, Mathews JTM, McDonnell GV, Mescall N, Norris S, Ramsay SJ, Rice CM, Russell MJ, Shawe-Taylor MJ, Williams TE, Harding KE, Robertson NP.
Tallantyre EC, et al. Among authors: mathews jtm.
Eur J Neurol. 2024 Apr 3:e16289. doi: 10.1111/ene.16289. Online ahead of print.
Eur J Neurol. 2024.
PMID: 38567516